Retinitis PigmentosaWang, QingCleveland, TheFoundation, Clinic
(CP10/00572 and PI13/02621 to JRE and a Research Intensification Contract to ALdM); the Basque Government’s Industry Department (SAIOTEK: SAIO11-PE11BN002; and SAIO12-PC12BN001 to JRE), and an unrestricted grant from the Retinitis Pigmentosa Patients of Gipuzkoa Foundation (BEGISARE). JR...
Veneto Eye Bank Foundation, 30174, Mestre, Venezia, Italy Vanessa Barbaro King Khaled Eye Specialist Hospital, 11462, Riyadh, Saudi Arabia Marco Mura Department of Medical Sciences, University of Ferrara, 44121, Ferrara, Italy Agnese Suppiej Ophthalmic Unit, Azienda Ospedaliero Universitaria di Ferrara...
Human donor eye tissue was provided by the Foundation Fighting Blindness, and the Washington and Northern Idaho Lions' Sight Conservation Foundation, Seattle, Washington. Each author has stated that he/she has no proprietary interest in the development or marketing of any drug or piece of equipment...
We thank the patients for participation and E. de Castro for help. This work was supported by grants from Foundation Fighting Blindness (A.G., S.G.J.), Deutsche Forschungsgemeinschaft (A.G., E.A.-S.), British Retinitis Pigmentosa Society (A.G., D.A.T.), March of Dimes Birth Def...
This work was supported by the ProRetina foundation, the Kerstan Foundation, Deutsche Forschungsgemeinschaft (DFG TR 1238/4-1), Swiss National Science Foundation (31003A_173008), BMBF (FKZ: 01EK1613E), and GC2018-098557-B-I00 from MCIU/AEI/FEDER, UE. RGS is a recipient of a JIN ...
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK Jasmina Cehajic-Kapetanovic, Kanmin Xue, Cristina Martinez-Fernandez de la Camara, Anika Nanda, Alexandra Davies, Laura J. Wood, Anna Paola Salvetti, James W. Aylward, Alun R. Barnard, Jasleen K. Jolly & Rober...
(drs den hollander and cremers); the foundation fighting blindness canada, canadian institute of health research, fond de la recherche en santé du québec, reseau vision, and national intitutes of health (dr koenekoop); organización nacional de ciegos, fis ps09/00459, and ciberer (isciii)...
Base editing technology is an ideal solution for treating pathogenic single-nucleotide variations (SNVs). No gene editing therapy has yet been approved for eye diseases, such as retinitis pigmentosa (RP). Here, we show, in the rd10 mouse model, which car
作者: L Gurses,O Gurbuz,Z Demircay,E Kotiloglu 展开 摘要: Case 1 A 28-year-old woman with skin type 2 was first seen in May 1997 with a 10-year history of a recurrent pruritic eruption in the intermammary area. Her medical history was not significant regarding a systemic disease...